Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements (Narrative) (Details)

v3.26.1
Fair Value Measurements (Narrative) (Details) - USD ($)
$ in Thousands, shares in Millions
3 Months Ended
Jul. 05, 2024
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Fair Value Measurements        
Impairments or other adjustments to fair value   $ 0    
Common stock warrant liabilities   0   $ 1
Transfer between level 1 to 2   0    
Transfer between level 2 to 1   0    
Transfer between level 1 to 3   0    
Change in fair value of investment   (1,047) $ 0  
Level 3 | Aevitas        
Fair Value Measurements        
Fair value option and estimated the fair value   $ 2,600    
9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.001 par value        
Fair Value Measurements        
Dividend rate percentage 9.375%      
9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.001 par value | Cyprium        
Fair Value Measurements        
Dividend rate percentage   9.375%    
Change in fair value of investment   $ (7,100)    
Avenue | Common Stock Warrant        
Fair Value Measurements        
Common stock warrant liabilities   $ 0   $ 1,000
Urica | Crystalys Therapeutics, Inc        
Fair Value Measurements        
Additional shares on anti-dilution provisions   2.3    
Increased carrying amount   $ 1,000    
Urica | Crystalys Therapeutics, Inc | Level 3        
Fair Value Measurements        
Estimated fair value   $ 16,100